Literature DB >> 8891465

Common ocular infections. A prescriber's guide.

S P Donahue1, J M Khoury, R P Kowalski.   

Abstract

While most ocular infections are benign, others can be associated with devastating visual consequences. Most patients present with either ocular discharge, visual symptoms or a red or painful eye. The primary care physician is usually the first to evaluate these patients. We have separated ocular infections into 3 groups. Infections affecting the cornea and conjunctiva often present with eye pain and a red eye; noninfectious aetiologies can have a similar presentation. Infections inside the eye (endophthalmitis) often have devastating consequences. They usually occur following penetrating ocular trauma or after intraocular surgery. Prompt referral to an ophthalmologist is crucial. Infections in the soft tissue surrounding the eye (ocular adnexa and orbit) can involve the eye indirectly and can spread from the orbit into the brain. The purpose of this article is to review ocular infections and current opinion regarding treatment. A general guideline should be that the approach to treatment be governed by the severity of symptoms and the magnitude of possible consequences. Mild external infections can be typically treated empirically. Severe conjunctivitis, and any corneal infection, require aggressive management, often including cultures and broad spectrum antibiotics; cultures are often used to guide treatment. Devastating vision loss can occur, even with aggressive management. Preseptal cellulitis in adults and older children can be managed conservatively with oral antibiotics if the orbit and optic nerve are not involved and the patient is otherwise healthy. Orbital or optic nerve involvement, on the other hand, demands orbital imaging and more aggressive intervention. Patients who have had recent surgery are at risk for developing endophthalmitis. Complaints of pain or a red eye must be taken very seriously. These patients must be considered to have an intraocular infection until it can be ruled out, and should be aggressively managed by a physician trained in eye diseases and surgery.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891465     DOI: 10.2165/00003495-199652040-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  58 in total

1.  Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin.

Authors:  B P Conway; P A Campochiaro
Journal:  Arch Ophthalmol       Date:  1986-03

2.  Combined treatment of Acanthamoeba keratitis with propamidine, neomycin, and polyhexamethylene biguanide.

Authors:  J H Varga; T C Wolf; H G Jensen; V C Parmley; J J Rowsey
Journal:  Am J Ophthalmol       Date:  1993-04-15       Impact factor: 5.258

3.  Candida endophthalmitis.

Authors:  A E Uliss; J B Walsh
Journal:  Ophthalmology       Date:  1983-11       Impact factor: 12.079

4.  The relative risk of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses. A case-control study. Microbial Keratitis Study Group.

Authors:  O D Schein; R J Glynn; E C Poggio; J M Seddon; K R Kenyon
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

5.  Infectious endophthalmitis. Review of 36 cases.

Authors:  C A Puliafito; A S Baker; J Haaf; C S Foster
Journal:  Ophthalmology       Date:  1982-08       Impact factor: 12.079

6.  Comparison of topical ciprofloxacin to conventional antibiotic therapy in the treatment of ulcerative keratitis.

Authors:  D J Parks; D A Abrams; F A Sarfarazi; H R Katz
Journal:  Am J Ophthalmol       Date:  1993-04-15       Impact factor: 5.258

7.  Periorbital cellulitis and paranasal sinusitis: a reappraisal.

Authors:  E D Shapiro; E R Wald; B A Brozanski
Journal:  Pediatr Infect Dis       Date:  1982 Mar-Apr

8.  The incidence of ulcerative keratitis among users of daily-wear and extended-wear soft contact lenses.

Authors:  E C Poggio; R J Glynn; O D Schein; J M Seddon; M J Shannon; V A Scardino; K R Kenyon
Journal:  N Engl J Med       Date:  1989-09-21       Impact factor: 91.245

9.  The management of sinogenic orbital complications.

Authors:  B Singh
Journal:  J Laryngol Otol       Date:  1995-04       Impact factor: 1.469

10.  A prospective, masked clinical trial of trifluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis.

Authors:  J B Ward; L G Siojo; S G Waller
Journal:  Cornea       Date:  1993-05       Impact factor: 2.651

View more
  7 in total

1.  The role of topical moxifloxacin, a new antibacterial in Europe, in the treatment of bacterial conjunctivitis.

Authors:  Jose Benitez-Del-Castillo; Yves Verboven; David Stroman; Laurent Kodjikian
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Acute infectious conjunctivitis in childhood.

Authors:  R Chawla; J D Kellner; W F Astle
Journal:  Paediatr Child Health       Date:  2001-07       Impact factor: 2.253

3.  Chlamydial conjunctivitis presenting as pre septal cellulitis.

Authors:  Suzannah R Drummond; Charles J M Diaper
Journal:  Head Face Med       Date:  2007-03-14       Impact factor: 2.151

Review 4.  Navigating Market Authorization: The Path Holoclar Took to Become the First Stem Cell Product Approved in the European Union.

Authors:  Graziella Pellegrini; Diego Ardigò; Giovanni Milazzo; Giorgio Iotti; Paolo Guatelli; Danilo Pelosi; Michele De Luca
Journal:  Stem Cells Transl Med       Date:  2017-12-27       Impact factor: 6.940

Review 5.  Emerging antimicrobial resistance and need for antimicrobial stewardship for ocular infections in India: A narrative review.

Authors:  Partha Biswas; Sneha Batra; Neha Gurha; Nitin Maksane
Journal:  Indian J Ophthalmol       Date:  2022-05       Impact factor: 2.969

6.  Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics.

Authors:  Joseph S Bertino
Journal:  Clin Ophthalmol       Date:  2009-09-24

Review 7.  Estimate of the direct and indirect annual cost of bacterial conjunctivitis in the United States.

Authors:  Andrew F Smith; Curtis Waycaster
Journal:  BMC Ophthalmol       Date:  2009-11-25       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.